With the ever-growing prevalence of drug-resistant pathogens, it has never been more important that we refresh the drug pipeline with new antimicrobials that act on new targets or exhibit novel modes of action. The recent COVID pandemic has served to highlight the importance of developing effective treatments for infection, driving the recent resurgence in anti-infectives drug discovery and development of innovative technologies and approaches for combating infection through more effective detection and diagnosis methods.
This two-day symposium will examine the latest advances in anti-infectives drug discovery from a medicinal chemist’s perspective, focusing on the particular challenges associated with developing anti-infectives whilst also showcasing emerging strategies for tackling infection.
Presentations
Date: Monday, 13 May
Time: 15:45-17:00
| High-throughput drop-out screening of an intracellular cyclic peptide library for the identification of new antibiotics Ali Tavassoli, Professor of Chemical Biology, University of Southampton |
| The Open Science Discovery of DNDi-6510: an orally bioavailable SARS-CoV2 anti-viral Ed Griffen, Cofounder, MedChemica |
| Oral Protease Inhibitors for the Treatment of COVID-19 Dafydd Owen, Senior Scientific Director, Medicinal Chemistry , Pfizer |
